v3.26.1
Note 11 - Segment Information - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Revenue (a): $ 60,138 $ 59,543
Depreciation in cost of revenue 745 810
Total segment cost of revenue 21,126 22,604
Gross Profit (c) 39,012 36,939
Operating expense 31,981 33,875
Operating income 7,031 3,064
Non-operating expense, net 2,678 (3,948)
Operating Segments [Member] | Sterilization and Disinfection Control [Member]    
Revenue (a): [1],[2],[3] 24,505 25,410
Depreciation in cost of revenue 437 450
Amortization in cost of revenue 121 139
Other cost of revenue (b) [4] 6,788 6,655
Total segment cost of revenue 7,346 7,244
Gross Profit (c) [5] 17,159 18,166
Operating Segments [Member] | Biopharmaceutical Development [Member]    
Revenue (a): [1],[2] 12,059 11,486
Depreciation in cost of revenue 78 89
Amortization in cost of revenue 379 372
Other cost of revenue (b) [4] 4,020 4,719
Total segment cost of revenue 4,477 5,180
Gross Profit (c) [5] 7,582 6,306
Operating Segments [Member] | Calibration Solutions [Member]    
Revenue (a): [1],[2] 13,285 12,350
Depreciation in cost of revenue 111 105
Amortization in cost of revenue 0 0
Other cost of revenue (b) [4] 5,143 5,203
Total segment cost of revenue 5,254 5,308
Gross Profit (c) [5] 8,031 7,042
Operating Segments [Member] | Clinical Genomics [Member]    
Revenue (a): [1],[2] 10,289 10,297
Depreciation in cost of revenue 119 166
Amortization in cost of revenue 191 191
Other cost of revenue (b) [4] 3,739 4,515
Total segment cost of revenue 4,049 4,872
Gross Profit (c) [5] 6,240 5,425
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]    
Revenue (a): [1],[2] 60,138 59,543
Depreciation in cost of revenue 745 810
Amortization in cost of revenue 691 702
Other cost of revenue (b) [4] 19,690 21,092
Total segment cost of revenue 21,126 22,604
Gross Profit (c) [5] 39,012 36,939
Operating expense 31,981 33,875
Operating income 7,031 3,064
Non-operating expense, net 2,678 (3,948)
Earnings before income taxes $ 4,353 $ 7,012
[1] Intersegment revenues are eliminated to arrive at consolidated totals. Revenues as presented are consistent with GAAP measurement principles and our CODM's review of segment information.
[2] Intersegment revenues are eliminated to arrive at consolidated totals. Revenues as presented are consistent with U.S. GAAP measurement principles and our CODM's review of segment information.
[3] Revenues of $9,289 from GKE are included in the Sterilization and Disinfection Control division during the year ended March 31, 2024 and represent sales of consumables made beginning from the acquisition date.
[4] Other segment cost of revenues for each reportable segment includes product costs, personnel costs (including stock-based compensation), and other manufacturing and overhead costs necessary to produce and sell our products and services, excluding depreciation and amortization.
[5] Gross profit as presented is consistent with U.S. GAAP measurement principles and our CODM's review of segment information.